![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1308, 2001-01, pp. : 15-15
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Which gemcitabine dosage schedule best in NSCLC?
Inpharma, Vol. 1, Iss. 1479, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Gemcitabine plus vinorelbine superior in NSCLC
Inpharma, Vol. 1, Iss. 1251, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
RRM1-based tailored chemotherapy for NSCLC?
Inpharma, Vol. 1, Iss. 1432-1433, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Time to consider placebo effect in QOL studies in NSCLC?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 327, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Polymorphisms: prognostic factors in advanced NSCLC?
Inpharma, Vol. 1, Iss. 1454, 2004-01 ,pp. :